Bezafibrate for the treatment of primary sclerosing cholangitis

Journal of Gastroenterology

Volumn 45, Issue 7, 2010, Pages 758-762

  Mizuno, Suguru ^a   Hirano, Kenji ^a   Tada, Minoru ^a   Yamamoto, Keisuke ^a   Yashima, Yoko ^a   Yagioka, Hiroshi ^a   Kawakubo, Kazumichi ^a   Ito, Yukiko ^b   Kogure, Hirofumi ^a   Sasaki, Takashi ^a   Arizumi, Toshihiko ^a   Togawa, Osamu ^a   Matsubara, Saburo ^a   Nakai, Yousuke ^a   Sasahira, Naoki ^a   Tsujino, Takeshi ^a   Isayama, Hiroyuki ^a   Kawabe, Takao ^a   Omata, Masao ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

Bezafibrate; Drug therapy; Primary sclerosing cholangitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; PREDNISOLONE; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID; ANTILIPEMIC AGENT;

ARTICLE; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; DRUG EFFICACY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; ADULT; AGED; BLOOD; CHOLANGITIS, SCLEROSING; DRUG EFFECTS; ENZYMOLOGY; FEMALE; FOLLOW UP; LIVER FUNCTION TEST; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TIME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLANGITIS, SCLEROSING; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; HYPOLIPIDEMIC AGENTS;

EID: 77955654601     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0204-x     Document Type: Article

References (20)

1. P Angulo KD Lindor 1999 Primary sclerosing cholangitis Hepatology 30 325 332 10.1002/hep.510300101 1:STN:280:DyaK1MzhsFOksA%3D%3D 10385674 (Pubitemid 29300604)
2. MK Porayko RH Wiesner NF LaRusso J Ludwig RL MacCarty BL Steiner, et al. 1990 Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease Gastroenterology 98 1594 1602 1:STN:280:DyaK3c3kvFKmtg%3D%3D 2338198
3. NF LaRusso BL Shneider D Black GJ Gores SP James E Doo, et al. 2006 Primary sclerosing cholangitis: summary of a workshop Hepatology 44 746 764 10.1002/hep.21337 16941705 (Pubitemid 44433732)
4. R Olsson KM Boberg OS de Muckadell S Lindgren R Hultcrantz G Folvik, et al. 2005 High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study Gastroenterology 129 1464 1472 10.1053/j.gastro.2005.08.017 1:CAS:528:DC%2BD2MXht12gsr7O 16285948 (Pubitemid 41597389)
5. B Zumoff 1977 Effect of clofibrate on plasma levels of alkaline phosphatase N Engl J Med 297 669 1:STN:280:DyaE2s3lsVyqtQ%3D%3D 895772
6. AP Day MD Feher R Chopra PD Mayne 1993 The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities Metabolism 42 839 842 10.1016/0026-0495(93)90056-T 1:STN:280:DyaK3szkslKhtA%3D%3D 8102192 (Pubitemid 23207110)
7. S Iwasaki K Tsuda H Ueta, et al. 1999 Bezafibrate may have a beneficial effect in precirrhotic primary biliary cirrhosis Hepatol Res 16 12 18 10.1016/S1386-6346(99)00033-9 (Pubitemid 29499826)
8. R Kita Y Kita-Sasai I Hanaoka T Kimura H Kokuryu S Takamatsu, et al. 2002 Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports) Am J Gastroenterol 97 1849 1851 10.1111/j.1572-0241.2002.05869.x 12135056
9. T Kurihara A Maeda M Shigemoto K Yamashita N Kamatani 2003 Efficacy of bezafibrate in a patient with primary sclerosing cholangitis J Gastroenterol 38 300 301 10.1007/s005350300053 12693383 (Pubitemid 36527137)
10. R Kita S Takamatsu T Kimura H Kokuryu Y Osaki N Tomono 2006 Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels J Gastroenterol 41 686 692 10.1007/s00535-006-1831-0 1:CAS:528:DC%2BD28XosFWrt7s%3D 16933007 (Pubitemid 44288534)
11. Lindor KD, LaRusso NF. Primary sclerosing cholangitis. In: Schiff ER, Sorrell MF, editors. Schiff's diseases of the liver. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 673-84.
12. ST Chari TC Smyrk MJ Levy MD Topazian N Takahashi L Zhang, et al. 2006 Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience Clin Gastroenterol Hepatol 4 1010 1016 10.1016/j.cgh.2006.05.017 16843735 quiz 934 (Pubitemid 44118845)
13. K Okazaki S Kawa T Kamisawa S Naruse S Tanaka I Nishimori, et al. 2006 Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal J Gastroenterol 41 626 631 10.1007/s00535-006-1868-0 16932998 (Pubitemid 44288525)
14. A Stiehl S Walker L Stiehl G Rudolph WJ Hofmann L Theilmann 1994 Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period J Hepatol 20 57 64 10.1016/S0168-8278(05)80467-2 1:STN:280:DyaK2c3mtVSrsA%3D%3D 8201224
15. KD Lindor 1997 Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group N Engl J Med 336 691 695 10.1056/NEJM199703063361003 1:CAS:528:DyaK2sXitValtbw%3D 9041099 (Pubitemid 27102683)
16. HJ van Hoogstraten FH Wolfhagen PC van de Meeberg H Kuiper GA Nix MC Becx, et al. 1998 Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses J Hepatol 29 417 423 10.1016/S0168-8278(98)80059-7 9764988 (Pubitemid 28396658)
17. S Iwasaki H Ohira S Nishiguchi M Zeniya S Kaneko M Onji, et al. 2008 The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study Hepatol Res 38 557 564 10.1111/j.1872-034X.2007.00305.x 1:CAS:528:DC%2BD1cXhtVSjtLfK 18452482 (Pubitemid 351622281)
18. YK Davies KM Cox BA Abdullah A Safta AB Terry KL Cox 2008 Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic J Pediatr Gastroenterol Nutr 47 61 67 10.1097/MPG.0b013e31816fee95 1:CAS:528:DC%2BD1cXot1ylsLw%3D 18607270
19. H Takikawa 1999 Recent status of primary sclerosing cholangitis in Japan J Hepatobiliary Pancreat Surg 6 352 355 10.1007/s005340050129 1:STN:280:DC%2BD3c7jtFShuw%3D%3D 10664280
20. K Hirano M Tada H Isayama Y Yashima H Yagioka T Sasaki, et al. 2008 Clinical features of primary sclerosing cholangitis with onset age above 50 years J Gastroenterol 43 729 733 10.1007/s00535-008-2216-3 18807135